PDCD1 and melanoma: In addition to the nivolumab, which is a fully human IgG4 mAb, two other PD-1 inhibitors, pembrolizumab (IgG4 mAb) and cemiplimab (IgG4 mAb), have demonstrated promising outcomes in melanoma and NSCLC patients [49].